Evidence map›Paper›PMID 37657282›Full record

ArticleSchizophrenia research2023

Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia.

Kira Griffiths, Sophie E Smart, Gareth J Barker, Bill Deakin, Stephen M Lawrie, Shon Lewis, David J Lythgoe, Antonio F Pardiñas, Krishna Singh, Scott Semple and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Kira GriffithsDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
Sophie E SmartMRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Gareth J BarkerNIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK.
Bill DeakinDivision of Neuroscience and Experimental Psychology, University of Manchester, M13 9PT, UK.
Stephen M LawrieDivision of Psychiatry, University of Edinburgh, Edinburgh, UK.
Shon LewisDivision of Psychology and Mental Health, University of Manchester, M13 9PT, UK; Greater Manchester Mental Health NHS Foundation Trust, Manchester M25 3BL, UK.
David J LythgoeNIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK.
Antonio F PardiñasMRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Krishna SinghCardiff University Brain Research Imaging Centre, Cardiff University, Cardiff CF24 4HQ, UK.
Scott SempleBHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4TJ, UK.
James T R WaltersMRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Stephen R WilliamsDivision of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, UK.
Alice EgertonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK.
James H MacCabeDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK. Electronic address: james.maccabe@kcl.ac.uk.
Cardiff University · GBKing's College London · GBSouth London and Maudsley NHS Foundation Trust · GBUniversity of Edinburgh · GBUniversity of Manchester · GBGreater Manchester Mental Health NHS Foundation Trust · GB

Funding

Department of HealthMedical Research Council MR/L010305/1Medical Research Council MR/L011794Medical Research Council MR/L011794/1
6 · The paper itself

Abstract

Dysfunction of glutamate neurotransmission has been implicated in the pathophysiology of schizophrenia and may be particularly relevant in severe, treatment-resistant symptoms. The underlying mechanism may involve hypofunction of the NMDA receptor. We investigated whether schizophrenia-related pathway polygenic scores, composed of genetic variants within NMDA receptor encoding genes, are associated with cortical glutamate in schizophrenia. Anterior cingulate cortex (ACC) glutamate was measured in 70 participants across 4 research sites using Proton Magnetic Resonance Spectroscopy (

Indexed as

SchizophreniaBrainGlutamic AcidGyrus CinguliHumansMultifactorial InheritanceProton Magnetic Resonance SpectroscopyReceptors, N-Methyl-D-AspartateGlutamic AcidReceptors, N-Methyl-D-Aspartateanterior cingulate cortexGlutamatemagnetic resonance spectroscopyschizophrenia

Identifiers

PMID37657282
PMCPMC10873209
OpenAlexW4386281608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.